Bevacizumab: Side Effects, Uses & Monitoring
Facts extracted from current FDA product labeling for Bevacizumab. Educational only — not medical advice.
Labeled uses
LYTENAVA is indicated for the treatment of patients with neovascular (wet) age-related macular degeneration (nAMD).
Source: FDA labeling via NIH DailyMed (set 7f9a3014…). Not affiliated with FDA or NIH.
Medical disclaimer: Always consult a qualified healthcare professional about any medication.